Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $8.27, but opened at $8.67. Grifols shares last traded at $8.69, with a volume of 115,500 shares.

Analysts Set New Price Targets

Separately, Morgan Stanley assumed coverage on Grifols in a report on Wednesday, February 12th. They set an "overweight" rating on the stock.

Grifols Price Performance

The stock has a market capitalization of $5.80 billion, a PE ratio of 7.21 and a beta of 0.35. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company's 50 day simple moving average is $7.47 and its 200 day simple moving average is $8.16.

Institutional Trading of Grifols

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Soleus Capital Management L.P. grew its stake in shares of Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock valued at $49,144,000 after buying an additional 2,083,722 shares during the period. Norges Bank purchased a new stake in shares of Grifols during the 4th quarter valued at $14,434,000. Whitebox Advisors LLC grew its stake in shares of Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock valued at $37,487,000 after buying an additional 1,519,093 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock valued at $17,782,000 after buying an additional 1,181,959 shares during the period. Finally, Anthracite Investment Company Inc. purchased a new stake in shares of Grifols during the 3rd quarter valued at $5,457,000.

Remove Ads

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.